[{"NetIncomeLoss_1_Q3_USD":-35432000.0,"OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1_Q3_USD":0.0,"GeneralAndAdministrativeExpense_3_Q3_USD":32557000.0,"GeneralAndAdministrativeExpense_1_Q3_USD":13001000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":829973177.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":928022057.0,"AccruedLiabilitiesCurrent_0_Q3_USD":24615000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":-8494000.0,"RestrictedCashAndCashEquivalentsNoncurrent_0_Q3_USD":4441000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-286532000.0,"Depreciation_3_Q3_USD":5151000.0,"OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_3_Q3_USD":0.0,"OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_3_Q3_USD":0.0,"OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_1_Q3_USD":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1_Q3_shares":1882966.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3_Q3_USD":3583000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1_Q3_USD":-15522000.0,"AssetsCurrent_0_Q3_USD":426733000.0,"ContractWithCustomerLiability_0_Q3_USD":49800000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q3_USD":462000.0,"CommonStockSharesIssued_0_Q3_shares":928525410.0,"Assets_0_Q3_USD":479022000.0,"ShareBasedCompensation_3_Q3_USD":7352000.0,"OperatingLeaseRightOfUseAsset_0_Q3_USD":18775000.0,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":334388000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3_Q3_shares":14851182.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q3_USD":211000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3_Q3_USD":324000.0,"Liabilities_0_Q3_USD":102816000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":65791000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":24067000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_Q3_USD":-1023000.0,"PrepaidExpenseCurrent_0_Q3_USD":7754000.0,"OtherNonoperatingIncomeExpense_3_Q3_USD":-1501000.0,"OtherNonoperatingIncomeExpense_1_Q3_USD":-1689000.0,"IncomeTaxExpenseBenefit_3_Q3_USD":110000.0,"IncomeTaxExpenseBenefit_1_Q3_USD":15000.0,"CommonStockValue_0_Q3_USD":1325000.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0_Q3_security":23.0,"OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_3_Q3_USD":0.0,"OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_1_Q3_USD":0.0,"ForeignCurrencyTransactionGainLossUnrealized_3_Q3_USD":1102000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":339929000.0,"RecordedUnconditionalPurchaseObligation_0_Q3_USD":2500000.0,"CostsAndExpenses_3_Q3_USD":98348000.0,"CostsAndExpenses_1_Q3_USD":37068000.0,"IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_3_Q3_USD":-117000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_3_Q3_USD":78915000.0,"OtherAssetsCurrent_0_Q3_USD":2662000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-94709000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-35121000.0,"AmortizationOfIntangibleAssets_3_Q3_USD":718000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":78466000.0,"OperatingLeaseLiabilityNoncurrent_0_Q3_USD":21090000.0,"CommonStockParOrStatedValuePerShare_0_Q3_GBP":0.001,"IncreaseDecreaseInOtherNoncurrentAssets_3_Q3_USD":-2291000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3_Q3_USD":0.57,"OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_3_Q3_USD":76000.0,"ContractWithCustomerLiabilityRevenueRecognized_1_Q3_USD":400000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q3_USD":28503000.0,"OtherOperatingActivitiesCashFlowStatement_3_Q3_USD":2817000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_Q3_USD":-93369000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q3_USD":-35417000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":3280000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3_Q3_USD":-5061000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q3_USD":15698000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-24375000.0,"LiabilitiesCurrent_0_Q3_USD":34899000.0,"AccountsPayableCurrent_0_Q3_USD":4030000.0,"ContractWithCustomerLiabilityRevenueRecognized_3_Q3_USD":1500000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q3_USD":82907000.0,"ProceedsFromStockOptionsExercised_3_Q3_USD":5541000.0,"OtherAccruedLiabilitiesCurrent_0_Q3_USD":2784000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q3_USD":1970000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0_Q3_security":0.0,"AdditionalPaidInCapital_0_Q3_USD":932518000.0,"PaymentsToAcquireIntangibleAssets_3_Q3_USD":496000.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0_Q3_USD":135000000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_3_Q3_USD":0.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_1_Q3_USD":0.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":26943000.0,"NetIncomeLoss_3_Q3_USD":-93479000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":26825000.0,"PaymentsToAcquireMarketableSecurities_3_Q3_USD":363777000.0,"CommonStockSharesOutstanding_0_Q3_shares":928525410.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":27999000.0,"OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1_Q3_USD":76000.0,"CommonStockSharesAuthorized_0_Q3_shares":1038249630.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":2456000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":1193000.0,"OperatingIncomeLoss_3_Q3_USD":-95892000.0,"OperatingIncomeLoss_1_Q3_USD":-35875000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q3_USD":321442000.0,"IncomeTaxesReceivable_0_Q3_USD":13921000.0,"InvestmentIncomeInterest_3_Q3_USD":4024000.0,"InvestmentIncomeInterest_1_Q3_USD":2147000.0,"ContractWithCustomerLiabilityCurrent_0_Q3_USD":3635000.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":479022000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q3_USD":8127000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":7352000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":3280000.0,"OperatingLeaseLiabilityCurrent_0_Q3_USD":2619000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-0.11,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-0.04,"ProfitLoss_3_Q3_USD":-93479000.0,"OtherLiabilitiesNoncurrent_0_Q3_USD":615000.0,"OtherLiabilitiesCurrent_0_Q3_USD":107000.0,"StockholdersEquity_0_Q3_USD":376206000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q3_USD":46212000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":1174000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-549143000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1_Q3_USD":1.25,"IncreaseDecreaseInContractWithCustomerLiability_3_Q3_USD":48649000.0,"Ticker":"ADAP","CIK":"1621227","name":"ADAPTIMMUNE THERAPEUTICS PLC","OfficialName":"Adaptimmune Therapeutics plc American Depositary Shares","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"301181409.0","Country":"United Kingdom","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20201105"}]